ReviewJournal of clinical immunology2007
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Review in Journal of clinical immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 131 citations in OpenAlex.
- Trial
- Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.Clinical pharmacokinetics · 2016Trial
- Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2014Trial
- Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.Archives of neurology · 2009Trial
- Identification and Validation of Hub Genes in Hidradenitis Suppurativa.Clinical, cosmetic and investigational dermatology · 2025Article
- Occurrence of IL-1, IL-10, CD25, CD40, and CD69 in the tissue of palatine tonsils.Postepy dermatologii i alergologii · 2022Article
- Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse.Pathology oncology research : POR · 2020Article
- IL-2 receptors preassemble and signal in the ER/Golgi causing resistance to antiproliferative anti-IL-2Rα therapies.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- 40 years of the human T-cell leukemia virus: past, present, and future.F1000Research · 2019Review
- Cytokines in Cancer Immunotherapy.Cold Spring Harbor perspectives in biology · 2018Review
- Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Drug Discovery by Molecular Imaging and Monitoring Therapy Response in Lymphoma.International journal of molecular sciences · 2017Review
- Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents.CNS drugs · 2017Review
- Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.Annual review of immunology · 2017Review
- Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis.Therapeutic advances in neurological disorders · 2017Review
- Article
- Soluble interleukin-2 receptor α and interleukin-2 serum levels in patients with basal cell carcinoma.Postepy dermatologii i alergologii · 2016Article
- Spotlight on daclizumab: its potential in the treatment of multiple sclerosis.Degenerative neurological and neuromuscular disease · 2016Review
- Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis.Biologics : targets & therapy · 2016Review
- The Use of Biologic Therapies in Uveitis.Clinical reviews in allergy & immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Twenty-five years ago, we reported the production of the monoclonal antibody, anti-Tac that identifies the IL-2 receptor alpha subunit and blocks the interaction of IL-2 with this growth factor receptor. In 1997, daclizumab (Zenapax), the humanized form of this antibody, was approved by the FDA for use in the prevention of renal allograft rejection. In addition, we demonstrated that daclizumab is of value in the treatment of patients with noninfectious uveitis, multiple sclerosis, and the neurological disease human T-cell lymphotropic virus I associated myelopathy/tropical spastic paraparesis (HAM/TSP). Others demonstrated therapeutic efficacy with daclizumab in patients with pure red cell aplasia, aplastic anemia, and psoriasis. Thus, translation of basic insights concerning the IL-2/IL-2 receptor system obtained using the monoclonal antibody daclizumab provided a useful strategy for the prevention of organ allograft rejection and the treatment of patients with select autoimmune diseases or T-cell leukemia/lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.